The European Comission has approved AbbVie’s Humira for the treatment of chronic non-infectious anterior uveitis in children aged two years or older who have had an inadequate response to or are intolerant to conventional therapy.
Humira is now the only approved biologic treatment option for chronic non-infectious anterior uveitis in children aged two years and older in the European Union.
Uveitis is an inflammation of the iris, choroid and the ciliary body in the eye. If left untreated, the disease can cause severe vision loss.
